Log in to your Inderes Free account to see all free content on this page.

Vivesto

0.08 SEK

-1.93 %

Less than 1K followers

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-1.93 %

-8.66 %

-30.89 %

-29.75 %

-60.05 %

-62.68 %

-75.62 %

-97.53 %

-99.48 %

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Market cap

89.9M SEK

Turnover

104.12K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

7.5.

2026

General meeting '26

7.5.

2026

Interim report Q1'26

13.8.

2026

Interim report Q2'26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Press releaseyesterday

DNB Carnegie Access: Vivesto: Several inflection points approaching – Q4 review

Regulatory press release2/27/2026, 7:30 AM

New number of shares and votes in Vivesto

Regulatory press release1/29/2026, 8:40 PM

Vivesto carries out a directed share issue to guarantors in connection with the completed rights issue

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release1/23/2026, 4:45 PM

Vivesto announces outcome of the rights issue

Press release1/12/2026, 3:40 PM

DNB Carnegie Access: Vivesto: Intervju - Händelserikt år står för dörren

Regulatory press release1/2/2026, 1:30 PM

Vivesto publishes information document regarding the rights issue

Regulatory press release12/22/2025, 9:30 AM

Report from Extraordinary General Meeting in Vivesto AB

Press release12/16/2025, 7:00 AM

Vivesto signs Liberi Group to accelerate partnering activities for Paccal Vet and Cantrixil programs

Press release11/24/2025, 7:00 AM

Vivesto holds a live-streamed business update today November 24

Press release11/21/2025, 6:40 AM

DNB Carnegie Access: Vivesto: Raising capital – Q3 review

Press release11/20/2025, 10:15 AM

DNB Carnegie Access: Vivesto - Q3 25 - Rapportintervju

Regulatory press release11/20/2025, 7:35 AM

Notice of Extraordinary General Meeting in Vivesto AB

Regulatory press release11/20/2025, 7:30 AM

Vivesto resolves on a fully secured rights issue of approximately SEK 53.8 million, subject to approval by an Extraordinary General Meeting

Press release11/12/2025, 7:00 AM

Vivesto to hold live-streamed business update on November 24

Press release11/10/2025, 6:02 AM

DNB Carnegie Access: Vivesto: Positive interim readout from the Paccal Vet study

Regulatory press release11/7/2025, 2:15 PM

Vivesto reports positive interim results for Paccal Vet pilot study in dogs

Regulatory press release11/7/2025, 9:00 AM

Nomination Committee appointed for the Annual General Meeting 2026 in Vivesto

Press release11/5/2025, 11:56 AM

DNB Carnegie Access: Vivesto: Preclinical package strengthened

Press release11/4/2025, 7:00 AM

Vivesto receives positive new Cantrixil preclinical results in AML

Press release8/14/2025, 6:00 AM

First patient dosed in Vivesto’s Paccal Vet dose-finding study in cats

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.